CervoMed unveils 50 mg tablet, FDA lifts exposure cap enabling 100 mg BID regimen

CervoMed announced a new 50 mg neflamapimod tablet with improved PK and FDA removal of the prior plasma exposure limit enabling a planned 100 mg twice-daily regimen.Key Highlights:Original SEC Filing: CervoMed Inc. [ CRVO ] - 8-K - Sep. 28, 2026This is an AI-powered summary. It may contain inaccura…